Literature DB >> 20504981

In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial.

M A Pfaller1, R Hollis, B P Goldstein, S Messer, D Diekema, T Henkel.   

Abstract

The efficacy of anidulafungin, an echinocandin antifungal agent with potent anti-Candida activity, in treating esophageal candidiasis was tested in a double-blind study versus oral fluconazole. Isolates were identified and tested for susceptibility. Candida albicans represented >90% of baseline isolates. The MIC(90) of anidulafungin for all strains was 0.06 mg/liter.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20504981      PMCID： PMC2897519          DOI： 10.1128/JCM.00806-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  18 in total

1.  In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species.

Authors:  J A Karlowsky; G A Harding; S A Zelenitsky; D J Hoban; A Kabani; T V Balko; M Turik; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

2.  Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.

Authors:  A H Groll; D Mickiene; R Petraitiene; V Petraitis; C A Lyman; J S Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

3.  Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis.

Authors:  J D Cartledge; J Midgley; B G Gazzard
Journal:  AIDS       Date:  1997-12       Impact factor: 4.177

4.  Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.

Authors:  E J Ernst; M E Klepser; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

5.  In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

Authors:  M A Pfaller; D J Diekema; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

6.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

7.  The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients.

Authors:  M Bonacini; T Young; L Laine
Journal:  Arch Intern Med       Date:  1991-08

8.  Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; R N Jones; J Turnidge; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

9.  A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.

Authors:  David S Krause; A E Simjee; Christo van Rensburg; Johann Viljoen; Thomas J Walsh; Beth P Goldstein; Michele Wible; Timothy Henkel
Journal:  Clin Infect Dis       Date:  2004-08-27       Impact factor: 9.079

10.  Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method.

Authors:  María Pilar Arévalo; Alfonso-Javier Carrillo-Muñoz; Javier Salgado; Delia Cardenes; Sonia Brió; Guillermo Quindós; Ana Espinel-Ingroff
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790
View more
  1 in total

1.  Elevated chitin content reduces the susceptibility of Candida species to caspofungin.

Authors:  Louise A Walker; Neil A R Gow; Carol A Munro
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.